Webinars

Minimize Risk With Rapid At-Line Concentration Measurement in Downstream Bioprocessing Applications

This webcast features: Paul Mania, Bioanalytics Applications Specialist, Repligen. Traditional UV/Vis spectroscopy uses fixed pathlengths to measure different analytes, such as nucleic acids, proteins, and cells from biological samples. These samples are often limited in volume or highly concentrated, which presents various challenges. The CTech™ SoloVPE® System uses a patented variable pathlength technology (VPT) to accurately measure the targeted concentration of various analytes. The system measures concentrations without being dependent on sample volume or sample concentration, removing any dilution requirements,…

Developing a Platform for Large-Scale Lentiviral Manufacture

This webcast features: Yiyu Dong, PhD, Associate Director of Viral Vector Process Technology Development (VVPTD), WuXi Advanced Therapies. Due to their capability for long-term transgene expression, large packaging capacity and ability to transduce postmitotic and quiescent cells, lentiviral vectors have become increasingly popular gene delivery tools for cell and gene therapies in recent years. However, capacity for lentiviral vector manufacture is a major industry bottleneck. WuXi Advanced Therapies has developed a lentiviral suspension manufacturing platform using OXGENE’s XLenti™ packaging plasmids.…

Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability

This webcast features: Nuska Tschammer, Head of DEL Lab Operations, WuXi AppTec. In recent years, increasing use of genetic, transcriptional and knock-out technologies led to numerous biologically validated targets, many of them in the category “first-in-class”. The core purpose of experimentally based tractability assessments is to evaluate if the target of interest can be modulated by a chemical entity. In the past, extensive HTS screening efforts were initiated to find starting points for the small molecule drug discovery. Today, direct…

Developing Methods for Comparability Studies of Therapeutic Monoclonal Antibodies: Minimize Time, Maintain Quality

This webcast features: Kalhari Silva, PhD, Head of Scientific Research, Custom Biologics, and Bob Dass, PhD, Senior Scientist, Octet Applications, Sartorius. Quantifying critical quality attributes accurately and precisely is an important aspect of regulatory compliance. There is greater demand to optimize processes by integrating advanced analytical tools that maximize quality, safety, and efficacy of biotherapeutics. Kalhari Silva, from Custom Biologics, will provide insight on how her team designs and establishes methods suitable for comparability studies that allow for their future…

BioProcess Insider State of the Industry – Live from BPI West, March 2022

BioProcess Insider’s State of the Industry takes a deeper look into the recent business news affecting the biomanufacturing industry, picking apart the numbers and highlighting potential trends. With a panel of industry experts, editor Dan Stanton discusses recent mergers and acquisitions in the bioprocess space, bottlenecks within the manufacturing sector, the continued head- and tailwinds COVID-19 is placing on businesses, and the evolution of the cell and gene therapy landscape and what that means for supply chains. Panelists: Frank Orlowski,…

WuXi Advanced Therapies Virology Operations: Cell & Gene Therapy Vector Regulatory Testing

This webcast features: Andreas Solomos, PhD, Director, Virology Operations, WuXi Advanced Therapies. Cell and gene therapy regulatory testing is a constantly evolving discipline as the field matures and data becomes more refined. Virology Operations at WuXi Advanced Therapies is able to provide testing for a variety of products ranging from small non-enveloped AAV vectors to large enveloped lentiviral vectors. Our testing is performed as quickly as testing parameters permit without sacrificing the quality and integrity of results. Our panel of testing…

Continuity of Methods: Characterizing Protein Therapeutic Stability From Developability Assessment to Release With Aura PTx

This webcast features: Bernardo Cordovez, CSO, Co-Founder, Halo Labs. Aura PTx is a complete protein therapeutic stability solution that enables characterization of subvisible particle aggregates from developability assessment through product release. Aura PTx is a high throughput analytical instrument that images, counts, sizes, and identifies subvisible particle aggregates, a critical quality attribute and the most important biologic stability parameter. Using volumes as low as 10 µL and with measurements of one minute per sample, Aura PTx enables rapid, highly contrast and…

Sustaining Project Management Business Continuity and Partnerships Throughout COVID

This webcast features: Patrick Haley, Sr. Director, Project Management & Business Operations, Avid Bioservices, Inc. The Avid project management office employed unique technology and communication techniques to maintain business continuity and material supply to our partners and the patients they serve throughout each COVID surge. This presentation will take a deep dive into the challenges and solutions encountered for each functional area in the biologics development and production process during the early COVID pandemic and later surges, while ultimately discussing…

Increasing Productivity of IVT Reaction Using At-Line Monitoring by HPLC Chromatography

This webcast features: Rok Sekirnik, PhD, Head of Process Development mRNA/pDNA, BIA Separations, now a Sartorius company. In Vitro Transcription (IVT) reactions are normally performed as batch processes. Considering their catalytic basis, it is possible to extend reaction times and yields by continuous addition of consumed reagents to the reaction mixture. However, fed-batch strategies reported to date have only managed to achieve a 40 – 100% increase in the production of mRNA. One of the main limitations of development has…

Improve Your Cell Line Development Workflows with Analytical Tools

This webcast features: Dirk MĂĽller, PhD, Manager of Media & Process Development, Sartorius, Lukas Klein, Scientist, Sartorius. Cell line development involves screening thousands of clones to find those that are stable, produce high yields of the bioproduct, and exhibit desired critical quality attributes (CQAs). While there are multiple CQAs that need to be monitored early in the development process, product yield, cell count and viability assessment remain the main attributes by which process conditions are optimized. Incorporating analytical techniques into…